Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 61

Showing 26-50 of 61 citing articles:

Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review
Ionas Papassotiriou, Antonios Kapogiannatos, C. Makatsoris, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5489-5489
Open Access | Times Cited: 2
An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
Qingmei Ye, Xin Zhou, Han Ren, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
The therapeutic potential of exosomes in lung cancer
Hongyuan Liang, Lingyun Zhang, Xiangxuan Zhao, et al.
Cellular Oncology (2023) Vol. 46, Iss. 5, pp. 1181-1212
Closed Access | Times Cited: 5
Inhibition of ULK1/2 and KRASG12Ccontrols tumor growth in preclinical models of lung cancer
Phaedra C. Ghazi, Kayla O’Toole, Sanjana Srinivas Boggaram, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
DDX18 Facilitates the Tumorigenesis of Lung Adenocarcinoma by Promoting Cell Cycle Progression through the Upregulation of CDK4
Bingbing Feng, Xinying Wang, Ding Qiu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4953-4953
Open Access | Times Cited: 1
Tumor promoting effect of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite accumulations and HIF-1α activation
Jingxing Yang, Yu-Chen Chuang, Jen‐Chih Tseng, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 1
Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells
Cindy Mendes, Isabel Lemos, Ana Hipólito, et al.
Bioscience Reports (2024) Vol. 44, Iss. 7
Open Access | Times Cited: 1
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study
Niels Reinmuth, Óscar Juan, Dariusz M. Kowalski, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4055-4067
Open Access | Times Cited: 1
Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells
Sanober Kafeel, Angela Ragone, Alessia Salzillo, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2633-2633
Open Access | Times Cited: 1
Prognostic Value of Sarcopenia in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer Undergoing Radiotherapy
Valerio Nardone, Alfonso Reginelli, Vittorio Patanè, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6673-6685
Open Access | Times Cited: 1
Recent trends and therapeutic potential of phytoceutical‐based nanoparticle delivery systems in mitigating non‐small cell lung cancer
Adam Haysom‐McDowell, Keshav Raj Paudel, Stewart Yeung, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 1
Mathematical Modeling Support for Lung Cancer Therapy—A Short Review
Jarosław Śmieja
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14516-14516
Open Access | Times Cited: 3
Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells via β-Catenin Proteasomal Degradation in Human Lung Cancer
Zin Zin, Satapat Racha, Masashi Yokoya, et al.
Marine Drugs (2023) Vol. 21, Iss. 12, pp. 627-627
Open Access | Times Cited: 3
Cell death mechanisms induced by green synthesized silver nanoparticles in combination with pheophorbide a-mediated photodynamic therapy against resistant MCF-7 cells overexpressed with p-glycoprotein
Alexander Chota, Blassan P. George, Heidi Abrahamse
(2023), pp. 30-30
Closed Access | Times Cited: 2
Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Target Therapy in Lung Adenocarcinoma Cell Lines
Mario Perez-Medina, José Sullivan López-González, Jesus J. Benito-Lopez, et al.
(2024)
Open Access
Major Facilitator Superfamily Domain Containing 12 Is Overexpressed in Lung Cancer and Exhibits an Oncogenic Role in Lung Adenocarcinoma Cells
Weijun Zhao, Xilin Hu, Zixuan Chen, et al.
DNA and Cell Biology (2024) Vol. 43, Iss. 7, pp. 331-340
Closed Access
DNAJC24 acts directly with PCNA and promotes malignant progression of LUAD by activating phosphorylation of AKT
Dongming Liu, Ran Zuo, Wei Liu, et al.
The FASEB Journal (2024) Vol. 38, Iss. 9
Closed Access
A Single-Center Experience in Combined Oncological–Surgical Treatment for Resectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Dan Levy Faber, Abed Agbarya, Ben Caspy, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 98-98
Open Access
Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines
Mario Perez-Medina, José Sullivan López-González, Jesus J. Benito-Lopez, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2490-2490
Open Access
The reactive stroma response regulates the immune landscape in prostate cancer
Rintu Thomas, John Michael Jerome, Kimiko L. Krieger, et al.
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 3, pp. 249-77
Open Access
eLife assessment: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
Rachel Evans
(2024)
Open Access
Reviewer #2 (Public Review): Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

(2024)
Open Access
Author response: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
Phaedra C. Ghazi, Kayla O’Toole, Sanjana Srinivas Boggaram, et al.
(2024)
Open Access
Novel DNA Repair Inhibitors Targeting XPG to Enhance Cisplatin Therapy in Non-Small Cell Lung Cancer: Insights from In Silico and Cell-Based Studies
Rita Manguinhas, Patrícia Serra, Nuno Gil, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3174-3174
Open Access
BUB1 Inhibition Overcomes Radio- and Chemoradiation Resistance in Lung Cancer
Shivani Thoidingjam, Sushmitha Sriramulu, Oudai Hassan, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3291-3291
Open Access

Scroll to top